Hyperphosphatemia

08/01/2008 - "This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance."
11/01/2014 - "Sevelamer is a phosphate binder that allows a better control of hyperphosphatemia, like other phosphate binder agents, but it has additional pleiotropic effects such as correcting certain abnormalities of lipid metabolism and clearance of several uremic toxins. "
07/01/2008 - "Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis. "
12/01/2007 - "Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. "
10/01/2008 - "In addition, the efficacy of sevelamer as a monotherapy in lowering phosphate to target levels in severe hyperphosphatemia remains debatable. "

01/01/2009 - "Visible derangements of calcium and phosphate levels start to become apparent when GFR falls below 40 ml/min. In some but not all patients, hyperphosphatemia may be a mortality risk predictor in CKD stages 4-5. There are only few treatment studies targeting hyperphosphatemia in these CKD stages. "
02/01/2008 - "An increasing body of evidence from experimental studies and in vivo data suggest that (I) a mineral imbalance with hyperphosphatemia and high-circulating calcium x phosphate product, (II) a deficiency of systemic or local calcification inhibitors, (III) death or 'damage' of vascular smooth muscle cells (VSMCs), and/or (IV) phenotypic transformation of VSMCs to osteo/chondrocytic cells may all act in concert to initiate and sustain vascular calcification. "
10/01/2014 - "Likewise, Nrf2 overexpression significantly decreased the formation of calcium deposit similar to the level of osteogenic staining in VSMCs, and DMF with Nrf2 knockdown failed to attenuate hyperphosphatemia induced vascular calcification. "
08/15/2014 - "Plasma biochemical analysis confirmed hyperphosphatemia (17.7 mg/dL) and low concentrations of total (4.3 mg/dL) and ionized (0.49 mmol/L) calcium. "
01/01/2014 - "LC is an ideal choice for second-line treatment of hyperphosphatemia after therapy failure or other contraindication for calcium agents. "

01/01/2013 - "Hyperphosphatemia through induction of vascular calcifications and decreased active vitamin D production leading to activation of the renin angiotensin system (RAS) along with defects in innate immunity are purported to be the proximate cause of CKD-MBD-associated mortality in CKD. "
01/01/2012 - "Essential therapy consists of early management of hyperphosphatemia and supplementation of active vitamin D."
03/01/2011 - "Subgroup analysis suggested a more pronounced survival benefit of liberal dietary phosphate prescription among nonblacks, participants without hyperphosphatemia, and those not receiving activated vitamin D. "
07/01/2007 - "Understanding the independent and context-dependent interactions between hyperphosphatemia and excessive vitamin D activity, as well as vascular calcifications and mortality in FGF23 null mice, may ultimately provide important insights into the management of clinical disorders of hyperphosphatemia and excess vitamin D activity."
07/01/2007 - "This suggests that hyperphosphatemia, rather than excessive vitamin D activity, is the major stimulus for vascular calcifications and contributes to the increased mortality in the FGF23-null mouse model. "

06/01/2011 - "Lanthanum carbonate (LC) is a nonaluminum, noncalcium phosphate binder that is effective for hyperphosphatemia in dialysis patients. "
01/01/2005 - "Lanthanum carbonate, a new noncalcium, nonaluminum phosphate binder, represents a promising treatment for hyperphosphatemia."
06/01/2003 - "Lanthanum carbonate (LC) (Fosrenol) is a novel new treatment for hyperphosphatemia. "
07/01/2009 - "Although data on the safety and efficacy of lanthanum carbonate in the treatment of hyperphosphatemia have been provided in long-term clinical studies, there is still an ongoing scientific debate about its possible long-term toxicity. "
04/01/2013 - "Long-term efficacy of lanthanum carbonate on hyperphosphatemia was examined in multicenter dialysis patients. "

07/01/2012 - "In Canada, first-line treatment of hyperphosphatemia consists primarily of calcium carbonate (CC). "
01/01/2015 - "An efficient, cost-effective, facile and commercially-viable formulation was demonstrated to deliver calcium carbonate for the treatment of hyperphosphatemia."
01/01/2015 - "Thus, phosphate binders such as calcium carbonate are commonly prescribed to CKD patients with hyperphosphatemia, but these have undesirable side effects. "
07/01/1998 - "Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis."
09/01/1991 - "Calcium carbonate in hyperphosphatemia."

01/01/2013 - "Hyperphosphatemia is a strong predictor of mortality in advanced CKD and is remediated via diet, phosphorus binders, and dialysis. "
02/01/1984 - "We speculated that continuous phosphorus infusion prevents the intermittent hyperphosphatemia of bolus phosphorus supplement and that continuous phosphorus infusion may be useful in the treatment of other hypophosphatemic states of infancy."
12/01/2006 - "Other investigators have noted an association of hyperphosphatemia and LVH; however, this study was the first to demonstrate that improvement in serum phosphorus is associated with reduction in LVM. "
03/01/2013 - "Evidence from these studies indicates that maintaining plasma phosphorus concentrations to within the International Renal Interest Society targets for CKD patients improves survival time and reduces clinical manifestations of hyperphosphatemia and SRHP. "
01/01/2013 - "The goal of this study was to analyse the TC of haemodialysis patients with hyperphosphatemia and its influence on serum phosphorus for 6 months follow up. "

05/01/2005 - "This study demonstrates that i.v. calcitriol, at initial doses of 0.5-1.5 microg, effectively reduces PTH levels in pediatric HD patients and that patients should be closely monitored for hyperphosphatemia and elevated Ca x P product."
01/01/2014 - "Contributing factors to the decreased calcemic response to PTH in CKD include: 1) hyperphosphatemia; 2) decreased serum calcitriol; 3) downregulation of the PTH1 receptor; 4) large, truncated amino-terminal PTH fragments acting at the carboxy-PTH receptor; and 5) uremic toxins. "
01/01/2010 - "Calcitriol concentration progressively decreased in dogs with CKD and differences became statistically significant by stage 3. HPTH and hyperphosphatemia occur frequently in dogs with naturally occurring CKD, even at early stages of CKD in some dogs. "
08/01/2000 - "The essence to medical management is to correct the two most important pathogenetic factors of HPT, hyperphosphatemia, and calcitriol deficiency. "
08/01/2000 - "If prevention fails, and even if severe HPT develops, many of these patients can still be controlled medically with correction of hyperphosphatemia and high doses of intravenous calcitriol. "

01/01/2013 - "Klotho deficiency accelerates aging and early death, effects at least partially due to excessive formation of 1,25(OH)2D3 and subsequent hyperphosphatemia. "
07/01/2009 - "Conversely, decreased FGF-23 activity results in hyperphosphatemia, increased 1,25(OH)(2)D levels, and abnormal soft-tissue calcification. "
12/01/2007 - "1,25(OH)(2)D(3) induces FGF23 78-fold in osteoblasts, and because FGF23 in turn represses 1,25(OH)(2)D(3) synthesis, a reciprocal relationship is established, with FGF23 indirectly curtailing 1,25(OH)(2)D(3)-mediated intestinal absorption and counterbalancing renal reabsorption of phosphate, thereby reversing hyperphosphatemia and preventing ectopic calcification. "
07/01/2007 - "Low FGF23 levels lead to hyperphosphatemia, elevated 1,25(OH)2D, and soft-tissue calcifications. "
04/01/2005 - "Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. "

07/01/2005 - "One of the top 2 common clinical treatments for hyperphosphatemia, calcium acetate, has an established history of efficacy since the 1980s, and has been shown to be cost effective and well tolerated, as well."
08/01/2002 - "A new gelcap form of calcium acetate has been introduced for control of hyperphosphatemia. "
01/01/1991 - "Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia."
12/01/2002 - "Since calcium acetate is the most cost-effective phosphate binder available, we recommend that it should remain the first line treatment of hyperphosphatemia in patients with ESRD."
05/01/2004 - "Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients."

01/01/2014 - "In our patient, the biochemical findings were normal, except for hyperphosphatemia and elevated alkaline phosphatase. "
01/01/2005 - "The patients had plasma iPTH levels 8-45 times higher than the top normal limit, high values of alkaline phosphatase, calcemia on the upper normal level, and hyperphosphatemia. "
01/01/1992 - "In contrast, hyperphosphatemia was a constant feature in all the patients, as was the absence of an increase in plasma alkaline phosphatase activity. "
08/01/2009 - "Preoperative symptoms were alleviated, and the serum PTH and alkaline phosphatase levels, hyperphosphatemia, and hypercalcemia were improved or normalized in most patients. "
03/01/2010 - "It is established that D-hypervitaminosis is accompanied by expressed hypercalcemia and hyperphosphatemia, by decreased contents of mineral components in the bone tissue and high activity of alkaline phosphatase in the blood serum. "

10/01/1999 - "Nocturnal hemodialysis achieves control of hyperphosphatemia without phosphate binders and a significant reduction in serum beta(2)-microglobulin levels. "
06/01/2004 - "This agent appears quite effective in the treatment of hyperphosphatemia in hemodialysis patients, and its usage may be advantageous in the treatment of dialysis patients."
04/01/1999 - "This agent appears quite effective in the treatment of hyperphosphatemia in hemodialysis patients, and its usage may be advantageous in the treatment of dialysis patients."
05/01/2014 - "It is concluded that all phosphate binders are safe and effective for the treatment of hyperphosphatemia in patients with ESKD undergoing hemodialysis. "
04/01/2013 - "Phosphate binders are useful for the treatment of hyperphosphatemia in hemodialysis (HD) patients. "

05/01/2006 - "The present study was designed to evaluate the efficacy of SH in the control of hyperphosphatemia and its effect, compared to AH, on serum lipid parameters in patients on continuous ambulatory peritoneal dialysis (CAPD). "
04/01/2004 - "Hyperphosphatemia is a frequent complication in Chinese CAPD patients. "
01/01/1989 - "Compared to HD the results were as follows: CAPD patients required significantly less aluminium to control hyperphosphatemia (0.16 vs. 0.49 g, p less than 0.005). "
01/01/1988 - "The problem of hypercalcemia and hyperphosphatemia can more easily controlled by CAPD than by hemodialysis. "
01/01/1994 - "We present a continuous ambulatory peritoneal dialysis patient with hypomagnesemia who developed hyperphosphatemia and profound hypocalcemia after oral phosphate replacement for severe hypophosphatemia. "

07/01/1999 - "However, with the exception of the beneficial effect on hyperphosphatemia of the very low protein diets supplemented with ketoacids, they have no proven effects on the other aspects of the uremic syndrome. "
08/20/1989 - "For therapy, apart from adequate antihypertensive management, a low-protein diet and treatment of the lipid metabolic disorder and the secondary hyperphosphatemia, is recommended in the patient with chronic renal disease."
01/01/1984 - "According to one hypothesis, hyperphosphatemia (high Ca X P product) is harmful for the diseased kidneys; protein restriction is beneficial, since a low protein diet is generally also low in phosphate. "
10/15/2015 - "Although dietary phosphate restriction is important for treating hyperphosphatemia in patients with chronic kidney disease, it remains unclear whether a low-protein diet (LPD), which contains low phosphate, has beneficial effects on malnutrition, inflammation, and vascular calcification. "
11/01/2013 - "We analyze the positive aspects of the low-protein diet for optimal control of hypertension, hyperphosphatemia, anemia, and proteinuria that is the goal of pharmacological management Chronic Kidney Disease patients. "

11/01/1998 - "Can pretransplantation hyperphosphatemia cause acute tubular necrosis in renal transplantation?"
03/01/2014 - "Including nine patients who underwent successful renal transplantation pre-operative bone symptoms, hypercalcemia, hyperphosphatemia, and an increased alkaline phosphatase levels were improved or resolved in all patients. "
06/01/2012 - "We then stopped vitamin D to manage the hypercalcemia and hyperphosphatemia; however, the TC did not regress after 1.5 years, thus the patient underwent renal transplantation. "
07/01/2010 - "In patients undergoing dialysis, FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D therapy, which in turn cause hypophosphatemia and reduced 1,25-dihydroxyvitamin D after kidney transplantation. "
01/01/1996 - "Several factors such as end-stage renal disease (azotemia), hyperparathyroidism, hyperphosphatemia, hypercalcemia, a high calcium-phosphate product, and the use of steroids and cytotoxic drugs after kidney transplantation are believed to interact in calciphylaxis. "

08/01/2011 - "Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding."